InflaRx Receives Nasdaq Notice for Sub-$1 Bid Price, 180-Day Deadline
InflaRx received a Nasdaq notice on March 11, 2026 after its ordinary share bid remained below the $1 minimum for 30 consecutive business days. The company has 180 calendar days until September 7, 2026 to regain compliance or risk transfer to the Nasdaq Capital Market.
1. Nasdaq Deficiency Notice Details
On March 11, 2026 InflaRx received a written notice from Nasdaq’s Listing Qualifications Department stating its ordinary share bid price had closed below the $1.00 minimum for 30 consecutive business days under Listing Rule 5450(a)(1). The notice has no immediate effect on listing or trading status.
2. Compliance Deadlines and Potential Transfer
Under Listing Rule 5810(c)(3)(A), InflaRx has 180 calendar days, until September 7, 2026, to restore its closing bid price above $1.00. Failure to comply may lead the company to apply for transfer to the Nasdaq Capital Market, which could grant an additional 180-day cure period to March 8, 2027.
3. Company Monitoring and Next Steps
InflaRx intends to closely monitor its share price and evaluate potential measures—such as investor engagement or corporate initiatives—to improve trading value. The company has not detailed specific actions but is committed to regaining compliance within the prescribed cure periods.